KR101922515B1 - 알코올 유발성 간 질환의 치료, 예방 및 역행 - Google Patents

알코올 유발성 간 질환의 치료, 예방 및 역행 Download PDF

Info

Publication number
KR101922515B1
KR101922515B1 KR1020097007164A KR20097007164A KR101922515B1 KR 101922515 B1 KR101922515 B1 KR 101922515B1 KR 1020097007164 A KR1020097007164 A KR 1020097007164A KR 20097007164 A KR20097007164 A KR 20097007164A KR 101922515 B1 KR101922515 B1 KR 101922515B1
Authority
KR
South Korea
Prior art keywords
ppar
liver
ethanol
insulin
igf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020097007164A
Other languages
English (en)
Korean (ko)
Other versions
KR20090086941A (ko
Inventor
라 몬트 수잔 마리 드
잭 레이먼드 완즈
Original Assignee
로드아일랜드하스피틀
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로드아일랜드하스피틀 filed Critical 로드아일랜드하스피틀
Publication of KR20090086941A publication Critical patent/KR20090086941A/ko
Application granted granted Critical
Publication of KR101922515B1 publication Critical patent/KR101922515B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/282—Artemisia, e.g. wormwood or sagebrush
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Environmental Sciences (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020097007164A 2006-09-08 2007-09-10 알코올 유발성 간 질환의 치료, 예방 및 역행 Expired - Fee Related KR101922515B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84298306P 2006-09-08 2006-09-08
US60/842,983 2006-09-08
PCT/US2007/019610 WO2008030595A2 (en) 2006-09-08 2007-09-10 Treatment, prevention, and reversal of alcohol-induced liver disease

Publications (2)

Publication Number Publication Date
KR20090086941A KR20090086941A (ko) 2009-08-14
KR101922515B1 true KR101922515B1 (ko) 2019-02-20

Family

ID=39157885

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020097007164A Expired - Fee Related KR101922515B1 (ko) 2006-09-08 2007-09-10 알코올 유발성 간 질환의 치료, 예방 및 역행

Country Status (8)

Country Link
US (1) US9717719B2 (https=)
EP (1) EP2061484B1 (https=)
JP (1) JP5864077B2 (https=)
KR (1) KR101922515B1 (https=)
AU (1) AU2007292874B2 (https=)
CA (1) CA2663115C (https=)
ES (1) ES2399147T3 (https=)
WO (1) WO2008030595A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007044487A1 (de) * 2007-09-18 2009-04-02 Universität Leipzig Verwendung des umgekehrten Zelldifferenzierungsprogramms (OCDP) zur Behandlung degenerierter, im pathologischen Zustand befindlicher Organe
JP2013194007A (ja) * 2012-03-21 2013-09-30 Cci Corp 抗酸化ストレス剤およびその用途
FR3004354A1 (fr) * 2013-04-10 2014-10-17 Alfact Innovation Composition comprenant la proteine hip/pap ou l'un de ses derives pour le traitement de la resistance a l'insuline
CA3091774A1 (en) * 2018-02-20 2019-08-29 EMULATE, Inc. Human microphysiological cell system for liver disease conversion with prov 1-18585 and prov 2-19154
US20210145774A1 (en) * 2019-11-14 2021-05-20 Cymabay Therapeutics, Inc. Treatment of alcoholic liver disease
CN113244225B (zh) * 2021-06-16 2022-06-28 昆明医科大学第一附属医院 土槿皮乙酸在制备抗血小板药物中的应用

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2058785B (en) * 1979-09-05 1983-05-25 Glaxo Group Ltd Phenol derivatives
US5525338A (en) 1992-08-21 1996-06-11 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin conjugates
US5223242A (en) 1985-11-05 1993-06-29 The General Hospital Corporation Negatively charged specific affinity reagents
US5166320A (en) 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
NZ244306A (en) 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5326770A (en) 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
DE4311651A1 (de) 1993-04-08 1994-10-13 Boehringer Ingelheim Int Virus für den Transport von Fremd-DNA in höhere eukaryotische Zellen
US5482698A (en) 1993-04-22 1996-01-09 Immunomedics, Inc. Detection and therapy of lesions with biotin/avidin polymer conjugates
DE4418965A1 (de) 1994-05-31 1995-12-07 Boehringer Ingelheim Int Verfahren zum Einbringen von Nukleinsäure in höhere eukaryotische Zellen
US5958371A (en) 1995-06-08 1999-09-28 Barnes-Jewish Hospital Site specific binding system, nuclear imaging compositions and methods
US5690907A (en) 1995-06-08 1997-11-25 The Jewish Hospital Of St. Louis Avidin-biotin conjugated emulsions as a site specific binding system
US5780010A (en) 1995-06-08 1998-07-14 Barnes-Jewish Hospital Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system
US5925657A (en) 1997-06-18 1999-07-20 The General Hospital Corporation Use of PPARγ agonists for inhibition of inflammatory cytokine production
AU8355998A (en) 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
US6713514B1 (en) 1999-04-19 2004-03-30 Lexicon Pharmaceuticals, Inc. PPAR-γ agonists as agents for the treatment of type II diabetes
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
US6462046B2 (en) 2000-01-06 2002-10-08 Advanced Syntech, Llc Heterocycle derivatives as PPAR-gamma agonists
EP1278749B1 (en) * 2000-04-25 2005-01-26 Bristol-Myers Squibb Company USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
WO2002002138A1 (en) 2000-07-03 2002-01-10 Probendo Pty Ltd Treating endotoxemia and related disorders with probiotics
CA2417005A1 (en) 2000-07-20 2002-01-31 Bristol Myers Squibb Company Regulators of ppar.delta.(.beta.) and their use in the treatment of obesity and insulin resistance
US6787552B2 (en) 2000-08-11 2004-09-07 Nippon Chemiphar Co., Ltd. PPAR delta activators
JP2004530408A (ja) 2000-10-19 2004-10-07 ザ ジェネラル ホスピタル コーポレーション 酵素活性の画像化法
UY27003A1 (es) 2000-11-06 2002-07-31 Schering Ag Productos radiofarmacéuticos para el diagnóstico de la enfermedad de alzheimer
US6869967B2 (en) 2001-07-30 2005-03-22 Novo Nordisk A/S Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives
WO2003016265A1 (en) * 2001-08-17 2003-02-27 Eisai Co., Ltd. Cyclic compound and ppar agonist
AU2003250441A1 (en) * 2002-08-20 2004-03-11 Koninklijke Philips Electronics N.V. Mobile network authentication for protecting stored content
CA2499380A1 (en) 2002-09-05 2004-03-18 Novo Nordisk A/S Novel vinyl carboxylic acid derivatives and their therapeutical use
WO2005009437A1 (en) * 2003-07-21 2005-02-03 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar
CN1897939A (zh) 2003-10-31 2007-01-17 詹森药业有限公司 适用作过氧化物酶体增生物激活受体（ppar）双重激动剂的苯氧基乙酸衍生物
EP1682507A1 (en) 2003-11-05 2006-07-26 F. Hoffmann-La Roche Ag Benzannelated compounds as ppar activators
EP1586573B1 (en) 2004-04-01 2007-02-07 Sanofi-Aventis Deutschland GmbH Oxadiazolones, processes for their preparation and their use as pharmaceuticals
EP1742923B1 (en) 2004-04-28 2009-05-27 F.Hoffmann-La Roche Ag Pyrazole phenyl derivatives as ppar activators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Transactions of the American Clinical and Climatological Association. 2004, Vol. 115, pp. 273-287*

Also Published As

Publication number Publication date
EP2061484B1 (en) 2012-11-07
ES2399147T3 (es) 2013-03-26
AU2007292874B2 (en) 2013-11-21
KR20090086941A (ko) 2009-08-14
EP2061484A2 (en) 2009-05-27
US9717719B2 (en) 2017-08-01
WO2008030595A2 (en) 2008-03-13
CA2663115A1 (en) 2008-03-13
EP2061484A4 (en) 2010-01-13
US20100021386A1 (en) 2010-01-28
JP5864077B2 (ja) 2016-02-17
WO2008030595A3 (en) 2008-06-26
AU2007292874A1 (en) 2008-03-13
JP2010502718A (ja) 2010-01-28
CA2663115C (en) 2015-04-28

Similar Documents

Publication Publication Date Title
Adachi et al. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells
Beyer et al. Impaired liver regeneration in Nrf2 knockout mice: role of ROS-mediated insulin/IGF-1 resistance
Menconi et al. Role of glucocorticoids in the molecular regulation of muscle wasting
Horike et al. AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3β and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase C gene expression in the liver
Kawaguchi et al. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet
Daitoku et al. Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR
Kong et al. Fibroblast growth factor 15–dependent and bile acid–independent promotion of liver regeneration in mice
Schaafsma et al. Insulin increases the expression of contractile phenotypic markers in airway smooth muscle
Varga et al. Disruption of renal arginine metabolism promotes kidney injury in hepatorenal syndrome in mice
Contreras et al. Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation
Valladares et al. TNF-α inhibits UCP-1 expression in brown adipocytes via ERKs: opposite effect of p38MAPK
KR101922515B1 (ko) 알코올 유발성 간 질환의 치료, 예방 및 역행
Zhang et al. Angiotensin II increases Pax-2 expression in fetal kidney cells via the AT2 receptor
Galli et al. Thiazolidinediones inhibit hepatocarcinogenesis in hepatitis B virus–transgenic mice by peroxisome proliferator‐activated receptor γ–independent regulation of nucleophosmin
Zhu et al. Downregulation of Sfrp5 in insulin resistant rats promotes macrophage-mediated pulmonary inflammation through activation of Wnt5a/JNK1 signaling
US9173875B2 (en) Treatment for nicotine-induced lung disease using peroxisome proliferator-activated receptor gamma agonists
JP2009120607A (ja) 新規な肝疾患の予防又は治療薬並びにインスリン抵抗性改善剤
KR20090066289A (ko) 알코올 유발성 뇌 질환의 치료, 예방 및 역행
Lee et al. Novel evidence in vivo: Berberine ameliorated glucocorticoid-induced post-natal growth retardation by regulating the GH/IGF-1 axis through KMT1A downregulation
Bu et al. Activated central galanin type 1 receptor alleviated insulin resistance in diabetic rat muscle
Johnson Apoptosis in the gastrointestinal tract
Hu et al. The effect of fatty acid-CoA ligase 4 on the growth of hepatic cancer cells
Woodmansee et al. The proliferative status of thyrotropes is dependent on modulation of specific cell cycle regulators by thyroid hormone
Xin-Long et al. mTOR partly mediates insulin resistance by phosphorylation of insulin receptor substrate-1 on serine307 residues after burn
Jung et al. IPMK modulates insulin-mediated suppression of hepatic glucose production

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

B601 Maintenance of original decision after re-examination before a trial
E801 Decision on dismissal of amendment
PB0601 Maintenance of original decision after re-examination before a trial

St.27 status event code: N-3-6-B10-B17-rex-PB0601

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

J301 Trial decision

Free format text: TRIAL NUMBER: 2014101008104; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20141229

Effective date: 20180330

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20180330

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2009 7007164

Appeal request date: 20141229

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2014101008104

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20211015

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20221122

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20221122